Junshi Biosciences Announces Inclusion of Junmikang® (Adalimumab) in China's 2026 National Essential Medicines List

Jul 09, 2026 18:26 CST Updated 18:26

Junshi Biosciences

Innovative Drug Developer

Mabwell

Innovative Biopharmaceutical Company

On July 9, 2026 (Beijing Time), Junshi Biosciences (1877.HK, 688180.SH) announced thatJunmaikang^®(Adalimumab Injection) has been included in the new edition of the "National Essential Medicines List (2026 Edition)", continuously benefiting patients with chronic autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, and psoriasis.

The National Essential Medicines List is the core inventory of pharmaceuticals in China designed to safeguard the basic healthcare needs of the public, with selection criteria focused on necessity for prevention and treatment, proven efficacy, and equitable accessibility. The list implements a dynamic optimization and adjustment mechanism; each update involves a comprehensive assessment based on changes in the domestic disease spectrum and clinical diagnostic and treatment needs, with inclusion signifying recognition of the drug's essential clinical demand. Drugs included in the Essential Medicines List enjoy priority assurance status within the diagnosis and treatment systems of public medical institutions at all levels across China, facilitating standardized prescription refills for patients with chronic diseases closer to home, reducing the costs associated with repeated visits and medication dispensing, and enhancing the convenience of treatment.

Junmaikang^®(Adalimumab Injection) was jointly developed by Junshi Biosciences and Mabwell, received its initial approval for marketing in China in 2022, and has been included in the National Reimbursement Drug List (Category B). Currently, Junmaikang^®The product has received approval for a total of eight indications in China, including rheumatoid arthritis, ankylosing spondylitis, psoriasis, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, Crohn’s disease, and pediatric Crohn’s disease. Collaborations for this product now span 17 countries, with marketing applications submitted in seven countries; it was approved for market launch in Indonesia in 2025.

1. This material is intended to convey cutting-edge information, does not constitute promotion of any products, and should not be used as clinical medication guidance.

2. For specific information on disease diagnosis and treatment, please follow the advice and guidance of healthcare professionals.

About Junshi Biosciences

Junshi Biosciences (688180.SH, 1877.HK), established in December 2012, is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies. Leveraging its exceptional drug discovery capabilities, robust biotechnology R&D strength, and large-scale manufacturing capacity, the company has successfully developed a portfolio of drugs with international competitiveness and built a tiered pipeline of candidates in development. Its therapeutic areas cover malignancies, autoimmune diseases, chronic metabolic disorders, and infectious diseases, while its innovative modalities span frontier directions such as monoclonal antibodies, small molecules, antibody-drug conjugates (ADCs), bispecific/multispecific antibodies, fusion proteins, nucleic acid-based therapeutics, and vaccines. To date, the company has commercialized five products domestically or overseas, including toripalimab (Tuoyi), a PD-1 inhibitor independently developed in China, which has been approved for marketing in more than 40 countries and regions worldwide, including China, the United States, and Europe.^®）。

Junshi Biosciences is committed to its mission of “making world-class, trustworthy innovative medicines accessible to patients.” Rooted in China with a global footprint, the Company currently employs nearly 3,000 people worldwide, primarily located in Maryland (USA), and Shanghai, Suzhou, Beijing, and Guangzhou (China).